Go Pro
NASDAQ:COCH

Envoy Medical Q1 2026 Earnings Report

Envoy Medical logo
$0.74 +0.03 (+4.65%)
Closing price 09/11/2026 03:53 PM Eastern
Extended Trading
$0.73 -0.02 (-2.29%)
As of 09/11/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Envoy Medical EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Envoy Medical Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.10 million
Beat/Miss
Missed by -$61.00 thousand
YoY Revenue Growth
N/A

Envoy Medical Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Envoy Medical's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Envoy Medical Earnings Headlines

ENVOY MEDICAL INC 0,691 +2,92 %
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.tc pixel
See More Envoy Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Envoy Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Envoy Medical and other key companies, straight to your email.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals. The company works closely with healthcare providers to integrate its device into patient care pathways, supporting therapy both in clinical environments and at home.

Headquartered in the Minneapolis–Saint Paul metropolitan area, Envoy Medical currently serves the U.S. market and is evaluating opportunities for expansion into select international regions. Its leadership team combines expertise in medical device development, rehabilitation sciences and commercial operations, backed by private financing aimed at advancing innovative therapies for neurological and musculoskeletal disorders.

View Envoy Medical Profile